Skip to main content

Mpox (Monkeypox)

2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
MVA-BN standard regimenPhase 3
BioNTech
BioNTechCA - San Diego
1 program
1
BNT166aPhase 21 trial
Active Trials
NCT07379580Recruiting310Est. Jun 2027
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Tecovirimat Oral Capsule [Tpoxx]N/A1 trial
Active Trials
NCT06721585Completed328Est. Aug 2025
Bavarian Nordic
Bavarian NordicDenmark - Kvistgard
1 program
MVA-BN standard regimenPHASE_31 trial
Active Trials
NCT06844487Active Not Recruiting344Est. May 2027

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
Bavarian NordicMVA-BN standard regimen
BioNTechBNT166a
Allergy TherapeuticsTecovirimat Oral Capsule [Tpoxx]

Clinical Trials (3)

Total enrollment: 982 patients across 3 trials

NCT06844487Bavarian NordicMVA-BN standard regimen

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Start: May 2025Est. completion: May 2027344 patients
Phase 3Active Not Recruiting
NCT07379580BioNTechBNT166a

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Start: Feb 2026Est. completion: Jun 2027310 patients
Phase 2Recruiting
NCT06721585Allergy TherapeuticsTecovirimat Oral Capsule [Tpoxx]

Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only

Start: Jul 2024Est. completion: Aug 2025328 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 982 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.